Johnson & Johnson has announced, in a press release, that its Janssen vaccine shows strong activity of neutralizing antibodiess versus the Delta variant. That is, it generates a strong and persistent activity against the rapidly widespread Delta variant and other highly prevalent SARS-CoV-2 viral variants.
We already know that the virus is mutating, and experts wonder if current vaccines can really be effective and show resistance against these strains.
“These new studies continue to show the ability of the Johnson & Johnson vaccine against Covid-19 to help protect the health of people around the world,” said Paul Stoffels, MD, Vice Chairman of the Executive Committee and Chief Scientific Officer of the company.
85% effective against Delta
A study has shown that Janssen elicited neutralizing antibody activity to this new variant, which is expected to be dominant in Spain shortly, at an even higher level than recently observed for Beta variant in South Africa, in which a high efficacy against severe / critical illness was shown.
Specifically, this trial concludes that the single-dose vaccine was 85 percent effective against severe / critical illness and demonstrated protection against hospitalization and death.
Thus, this vaccine was effective in all regions studied globally, including in South Africa and Brazil, where there was a high prevalence of fast-appearing Beta and Zeta variants during the study period.
Immune responses last at least 8 months
It is also concluded that the immune responses lasted at least eight months, this being the last data recorded in the study so far. To be more specific, the company has reported that the data showed that the T cell responses, including CD8 + T cells that identify and destroy infected cells, persisted during the eight-month period examined.
And it also protects from variants Gamma (P.1), Alpha (B.1.1.7), Epsilon (B.1.429), Kappa (B.1.617.1) and D614G, as well as the original strain.
Recall that the Janssen vaccine received authorization for emergency use and the World Health Organization (WHO) included it on its emergency use list on March 12, 2021.
Janssen is given in a single dose it is stable for two years when stored between -25 ° C and -15 ° C12. Once removed from the freezer, unopened vaccine can be stored refrigerated at 2-8 ° C, protected from light, for up to 3 months.